FDA Approves Briviact: Another US Epilepsy Win For UCB
This article was originally published in Scrip
Executive Summary
The FDA on Feb. 19 gave UCB SA another win in the epilepsy market with the US approval of Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients 16 years or older.